Judge Rules FDA Can Regulate Stem Cell Treatment As Drug

Law360, New York (July 24, 2012, 2:08 PM EDT) -- A Washington federal judge on Monday threw out a suit against the U.S. Food and Drug Administration challenging its regulation of a stem cell treatment, finding the procedure constitutes a drug and is subject to FDA enforcement.

While acknowledging that it was a “close question,” U.S. District Judge Rosemary M. Collyer granted summary judgment in favor of the FDA in a suit brought by Regenerative Sciences LLC over the company's trademarked Regenexx Procedure, which uses patients' stem cells from their own bone marrow to treat joint,...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

UNITED STATES OF AMERICA v. REGENERATIVE SCIENCES, LLC et al


Case Number

1:10-cv-01327

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Rosemary M. Collyer

Date Filed

August 6, 2010

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.